Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study

Host: Marlene Mimi Maeusli, PhD. <br> <p>A recent Danish population-based study evaluating real-world outcomes of ibrutinib in relapsed or refractory mantle cell lymphoma (MCL) found lower efficacy and tolerability compared to clinical trials, particularly among older patients and those with high-risk disease features. In this <i>AudioAbstract, </i>ReachMD's Dr. Mimi Maeusli explains how this evidence is reshaping our view of ibrutinib's clinical utility.</p>